Sneddon-Wilkinson Disease Induced by Sorafenib in a Patient with Advanced Hepatocellular Carcinoma
نویسندگان
چکیده
منابع مشابه
Sorafenib in advanced hepatocellular carcinoma.
BACKGROUND No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS In this multicenter, phase 3, double-blind, placebo-control...
متن کاملSorafenib Effectiveness in Advanced Hepatocellular Carcinoma
BACKGROUND Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare beneficiaries with advanced HCC. MATERIALS AND METHODS Patients with advanced HCC diagnosed fro...
متن کامل[subcorneal Pustular Dermatosis. (sneddon-wilkinson Disease)].
Subcorneal pustular dermatosis is a disease that has coalescent, flaccid, recurrent pustules. We do not know everything about its etiology or pathogenesis; however, its autoimmune mechanism links it with neoplastic or immunologic diseases. First line treatment is dapsone. We describe the case of a classic subcorneal pustular dermatosis in a patient in who we could not use dapsone (sulpha drugs ...
متن کاملSneddon- Wilkinson Disease in association with Non- Hodgkin Lymphoma
Sneddon-Wilkinson disease is a rare condition with chronic recurrent course. It may be a part of paraneoplastic manifestation of underlying malignancy. The disease is diagnosed on the basis of its characteristic clinical features and histopathology. A case of Sneddon –Wilkinson disease associated with non-hodgkin lymphoma in a 54 years old lady is presented.
متن کاملInterstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report
Sorafenib is a multikinase inhibitor currently approved in Japan for the treatment of unresectable hepatocellular carcinoma. Interstitial pneumonia induced by sorafenib may have a fatal outcome, and therefore, has recently been the focus of many studies. The current report presents an autopsy case of diffuse alveolar damage (DAD) that occurred in a 59-year-old male, who had been treated with so...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Internal Medicine
سال: 2015
ISSN: 0918-2918,1349-7235
DOI: 10.2169/internalmedicine.54.3675